Correlations between vaccinia-specific immune responses within a cohort of armed forces members

Viral Immunology

Volumn 24, Issue 5, 2011, Pages 415-420

  Umlauf, Benjamin J ^a   Ovsyannikova, Inna G ^a   Haralambieva, Iana H ^a   Kennedy, Richard B ^a   Vierkant, Robert A ^a   Pankratz, V Shane ^a   Jacobson, Robert M ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; SMALLPOX VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBODY TITER; ARMY; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; SINGLE DRUG DOSE; SMALLPOX; TH1 CELL; VACCINATION; VACCINIA VIRUS;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; CYTOKINES; FEMALE; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; MALE; MILITARY PERSONNEL; SMALLPOX VACCINE; TH2 CELLS; VACCINATION; VACCINIA; VACCINIA VIRUS; YOUNG ADULT;

VACCINIA VIRUS; VARIOLA VIRUS;

EID: 80054723800     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2011.0029     Document Type: Article

References (32)

1. Allmendinger J, Paradies F, Kamprad M, et al.: Determination of rubella virus-specific cell-mediated immunity using IFN gamma-ELISpot. J Med Virol 2010;82:335-340.
2. Amanna IJ, Messaoudi I, and Slifka MK: Protective immunity following vaccination: how is it defined? Hum Vaccin 2008;4:316-319.
3. Belshe RB, Newman FK, Frey SE, et al.: Dose-dependent neutralizing-antibody responses to vaccinia. J Infect Dis 2004;189:493-497. (Pubitemid 38210586)
4. Belyakov IM, Isakov D, Zhu Q, et al.: Enhancement of CD8 + T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host. J Immunol 2006;177:6336-6343. (Pubitemid 44628852)
5. Cohen JI, Hohman P, Fulton R, et al.: Kinetics of serum cy-tokines after primary or repeat vaccination with the smallpox vaccine. J Infect Dis 2010;201:1183-1191.
6. Corsini E, Vismara L, Lucchi L, et al.: High interleukin-10 production is associated with low antibody response to influenza vaccination in the elderly. J Leukoc Biol 2006;80:376-382. (Pubitemid 44835511)
7. Dhiman N, Ovsyannikova IG, Ryan JE, et al.: Correlations among measles virus-specific antibody, lymphoproliferation and Th1/Th2 cytokine responses following MMR-II vaccination. Clin and Exper Immunol 2005;142:498-504. (Pubitemid 41719846)
8. Dinarello CA: Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res 2004;10:201-222. (Pubitemid 39481010)
9. Earl PL, Moss B, Wyatt LS, and Carroll MW: Generation of recombinant vaccinia viruses. Curr Protoc Mol Biol 2001; Chap 16:Unit 16.
10. Earl PL, Cooper N, Wyatt LS, Moss B, and Carroll MW: Preparation of cell cultures and vaccinia virus stocks. Curr Protoc Mol Biol 2001;Chap 16:Unit 16.
11. Empig C, Kenner JR, Perret-Gentil M, et al.: Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine 2006;24:3686-3694.
12. Frey SE, Newman FK, Kennedy JS, et al.: Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine 2009;27: 1637-1644.
13. Garner-Spitzer E, Kundi M, Rendi-Wagner P, et al.: Correlation between humoral and cellular immune responses and the expression of the hepatitis A receptor HAVcr-1 on T cells after hepatitis A re-vaccination in high and low-responder vaccinees. Vaccine 2009;27:197-204.
14. Hayney MS, Buck JM, and Muller D: Production of inter-feron-gamma and interleukin-10 after inactivated hepatitis A immunization. Pharmacotherapy 2003;23:431-435. (Pubitemid 36384321)
15. Kennedy R, Pankratz VS, Swanson E, et al.: Statistical approach to estimate vaccinia-specific neutralizing antibody titers using a high throughput assay. Clin Vaccine Immunol 2009;16:1105-1112.
16. Kennedy RB, Ovsyannikova I, and Poland GA: Smallpox vaccines for biodefense. Vaccine 2009;27(Suppl 4):D73-D79.
17. Kennedy RB, Ovsyannikova IG, Jacobson RM, and Poland GA: The immunology of smallpox vaccines. Curr Opin Immunol 2009;21:314-320.
18. Kennedy RB, Ovsyannikova IG, Pankratz VS, et al.: Gender effects on humoral immune responses to smallpox vaccine. Vaccine 2009;27:3319-3323.
19. Manischewitz J, King LR, Bleckwenn NA, et al.: Development of a novel vaccinia-neutralization assay based on reporter-gene expression. J Infect Dis 2003;188:440-448. (Pubitemid 36960656)
20. McKinney BA, Reif DM, Rock MT, et al.: Cytokine expression patterns associated with systemic adverse events following smallpox immunization. J Infect Dis 2006;194:444-453. (Pubitemid 44162655)
21. Meseda CA, Garcia AD, Kumar A, et al.: Enhanced immu-nogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 2005;339:164-175. (Pubitemid 41169785)
22. Ovsyannikova IG, Jacobson RM, Ryan JE, et al.: HLA class II alleles and measles virus-specific cytokine immune response following two doses of measles vaccine. Immunogenetics 2005;56:798-807. (Pubitemid 40558083)
23. Ray CA, Black RA, Kronheim SR, et al.: Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the in-terleukin-1 beta converting enzyme. Cell 1992;69:597-604.
24. Rock MT, Yoder SM, Talbot TR, Edwards KM, and Crowe JE Jr: Adverse events after smallpox immunizations are associated with alterations in systemic cytokine levels. J Infect Dis 2004;189:1401-1410. (Pubitemid 38543589)
25. Rotz LD, Dotson DA, Damon IK, and Becher JA: Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep 2001;50:1-25.
26. Ryan JE, Dhiman N, Ovsyannikova IG, et al.: Response surface methodology to determine optimal cytokine responses in human peripheral blood mononuclear cells after smallpox vaccination. J Immunol Methods 2009;341:97-105.
27. Ryan JE, Ovsyannikova IG, Dhiman N, et al.: Inter-operator variation in ELISPOT analysis of measles virus-specific IFN-gamma secreting T cells. Scand J Clin Lab Invest 2005;65: 681-690.
28. Tosh PK, Kennedy RB, Vierkant RA, Jacobson RM, and Poland GA: Correlation between rubella antibody levels and cytokine measures of cell-mediated immunity. Viral Immunol 2009;22:451-456.
29. Umlauf BJ, Pinsky NA, Ovsyannikova IG, and Poland GA. Detection of vaccinia virus-specific IFN-g and IL-10 secretion from human PBMC and CD8+ T cells by ELISPOT. Methods in Molecular Biology. 2011. (In press).
30. Velu V, Saravanan S, Nandakumar S, et al.: Relationship between T-lymphocyte cytokine levels and sero-response to hepatitis B vaccines. World J Gastroenterol 2008;14:3534-3540.
31. Vollmar J, Arndtz N, Eckl KM, et al.: Safety and immuno-genicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006;24:2065-2070. (Pubitemid 43255148)
32. Xu R, Johnson AJ, Liggitt D, and Bevan MJ: Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol 2004;172:6265-6271. (Pubitemid 38621233)